stockrow
Friday 6 November 2026
Export ABCL’s income statement to Excel — free account
AbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
11.89
0.76
+6.83%
Follow ABCL
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
42.56 | 13.60 | 13.35 | 36.25 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(28.58) | (29.40) | (31.55) | 92.53 | |
P/B ratio |
1.56 | 1.06 | 1.13 | 2.68 | |
Price to Tangible BV |
1.71 | 1.16 | 1.24 | 2.96 | |
EV/Sales |
27.92 | 6.21 | 6.71 | 27.76 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(9.43) | (3.55) | (3.47) | (19.35) | |
EV/FCF |
(6.31) | (2.63) | (2.76) | (14.96) | |
Quick Ratio |
8.17 | 9.60 | 11.98 | 10.97 | |
Current Ratio |
10.10 | 11.32 | 14.05 | 12.77 | |
Net Debt/EBITDA |
7.54 | 27.05 | 10.84 | 10.47 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.03 | 0.06 | 0.06 | 0.05 | |
Operating CF/Net income |
0.92 | 3.88 | 0.78 | (0.47) | |
Capex/Depreciation |
(1.23) | (1.24) | (0.44) | (0.24) | |
Research and Development Expense of Revenue |
614.49% | 111.68% | 561.18% | 1,135.48% | |
Selling, General and Administrative Expense of Revenue |
278.70% | 38.39% | 148.33% | 341.98% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.07 | 0.06 | |
Share Based Compensation of Revenue |
155.16% | 28.77% | 144.47% | 303.36% | |
Graham Net Nets |
0.20 | 0.33 | 0.28 | 0.11 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.33%) | (14.33%) | (13.75%) | (6.88%) | |
Free Cash Flow Yield |
(10.39%) | (17.34%) | (18.19%) | (5.12%) | |
Revenue per Share |
0.03 | 0.15 | 0.03 | 0.01 | |
Operating CF per Share |
(0.18) | (0.12) | (0.11) | 0.08 | |
Capex per Share |
(0.03) | (0.03) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.21) | (0.15) | (0.12) | 0.08 | |
Cash per Share |
1.74 | 1.87 | 1.75 | 1.85 | |
Shareholders Equity per Share |
3.23 | 3.24 | 3.10 | 2.93 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.23 | 3.24 | 3.10 | 2.93 | |
Free Cash Flow |
(61.52) | (44.59) | (37.35) | 23.79 | |
Working Capital |
626.34 | 663.93 | 617.30 | 626.04 | |
Capital Expenditures |
(8.93) | (9.84) | (3.83) | (2.13) | |
Net Current Asset Value |
303.19 | 338.19 | 295.57 | 267.68 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.00 | 0.22 | 0.46 | 0.53 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
36.41 | 45.95 | 38.38 | 32.95 | |
Average Payables |
53.45 | 52.89 | 43.70 | 41.28 | |
Average Assets |
1,374.41 | 1,358.75 | 1,325.66 | 1,354.82 | |
Average Common Equity |
1,021.07 | 1,011.49 | 980.53 | 951.55 |
Columns are period end dates